Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD market SAN DIEGO, May 28, 2026 /PRNewswire/ --...
An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD market SAN DIEGO, May 28, 2026 /PRNewswire/ --...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.